Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
JPM26: Gilead eyes new deals from a 'position of strength'
Across virology, oncology and inflammation, Gilead has "the luxury of being selective" in the external assets it considers adding to its pipeline.
Darren Incorvaia
Jan 14, 2026 3:30am
Study finds HIV can evolve to resist lenacapavir—at a cost
Jan 7, 2026 2:00pm
Addition Tx does the math and emerges from stealth with $100M
Dec 17, 2025 7:45am
Merck's HIV combo matches Gilead's Biktarvy in phase 3 test
Nov 19, 2025 8:10am
NIH cuts disrupted hundreds of clinical trials, study finds
Nov 17, 2025 11:00am
Gilead settles on twice-yearly treatment partner for lenacapavir
Oct 30, 2025 6:37pm
